JP2008505190A - 骨の形成と再構築のための組成物および方法 - Google Patents
骨の形成と再構築のための組成物および方法 Download PDFInfo
- Publication number
- JP2008505190A JP2008505190A JP2007527363A JP2007527363A JP2008505190A JP 2008505190 A JP2008505190 A JP 2008505190A JP 2007527363 A JP2007527363 A JP 2007527363A JP 2007527363 A JP2007527363 A JP 2007527363A JP 2008505190 A JP2008505190 A JP 2008505190A
- Authority
- JP
- Japan
- Prior art keywords
- receptor
- protein
- lrp5
- bone
- lrp6
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 title claims 475
- 230000011164 ossification Effects 0.000 title claims 291
- 239000000203 mixture Substances 0.000 title claims 61
- 102000004169 proteins and genes Human genes 0.000 claims abstract 567
- 108090000623 proteins and genes Proteins 0.000 claims abstract 567
- 101001043594 Homo sapiens Low-density lipoprotein receptor-related protein 5 Proteins 0.000 claims abstract 468
- 102000013814 Wnt Human genes 0.000 claims abstract 203
- 108050003627 Wnt Proteins 0.000 claims abstract 203
- 210000000988 bone and bone Anatomy 0.000 claims abstract 113
- 108010006519 Molecular Chaperones Proteins 0.000 claims abstract 103
- 102100021926 Low-density lipoprotein receptor-related protein 5 Human genes 0.000 claims abstract 76
- 101150021503 Mesd gene Proteins 0.000 claims abstract 61
- 230000003993 interaction Effects 0.000 claims abstract 29
- 102100030074 Dickkopf-related protein 1 Human genes 0.000 claims abstract 22
- 101710099518 Dickkopf-related protein 1 Proteins 0.000 claims abstract 21
- 150000001875 compounds Chemical class 0.000 claims 522
- 150000002632 lipids Chemical class 0.000 claims 489
- 101001039199 Homo sapiens Low-density lipoprotein receptor-related protein 6 Proteins 0.000 claims 451
- 230000010072 bone remodeling Effects 0.000 claims 287
- 108090000765 processed proteins & peptides Proteins 0.000 claims 228
- 102000005962 receptors Human genes 0.000 claims 186
- 108020003175 receptors Proteins 0.000 claims 186
- 102000004196 processed proteins & peptides Human genes 0.000 claims 154
- 235000000346 sugar Nutrition 0.000 claims 138
- 239000000126 substance Substances 0.000 claims 122
- 102000004895 Lipoproteins Human genes 0.000 claims 120
- 108090001030 Lipoproteins Proteins 0.000 claims 120
- 125000000623 heterocyclic group Chemical group 0.000 claims 120
- 102000039446 nucleic acids Human genes 0.000 claims 120
- 108020004707 nucleic acids Proteins 0.000 claims 120
- 150000007523 nucleic acids Chemical class 0.000 claims 120
- 229930186217 Glycolipid Natural products 0.000 claims 115
- 150000003384 small molecules Chemical class 0.000 claims 115
- 230000004936 stimulating effect Effects 0.000 claims 115
- 125000004122 cyclic group Chemical group 0.000 claims 114
- 229920001184 polypeptide Polymers 0.000 claims 114
- 102000003886 Glycoproteins Human genes 0.000 claims 113
- 108090000288 Glycoproteins Proteins 0.000 claims 113
- 230000001737 promoting effect Effects 0.000 claims 108
- 241000124008 Mammalia Species 0.000 claims 98
- 206010028980 Neoplasm Diseases 0.000 claims 82
- 230000005856 abnormality Effects 0.000 claims 82
- 208000020084 Bone disease Diseases 0.000 claims 81
- 239000012634 fragment Substances 0.000 claims 79
- 150000008163 sugars Chemical class 0.000 claims 76
- 206010017076 Fracture Diseases 0.000 claims 71
- 206010061363 Skeletal injury Diseases 0.000 claims 69
- 230000012010 growth Effects 0.000 claims 63
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 62
- 208000010392 Bone Fractures Diseases 0.000 claims 56
- 239000005557 antagonist Substances 0.000 claims 54
- 102100040704 Low-density lipoprotein receptor-related protein 6 Human genes 0.000 claims 52
- 230000001225 therapeutic effect Effects 0.000 claims 52
- 230000027455 binding Effects 0.000 claims 50
- 102000015735 Beta-catenin Human genes 0.000 claims 48
- 108060000903 Beta-catenin Proteins 0.000 claims 48
- 230000003834 intracellular effect Effects 0.000 claims 47
- 238000009825 accumulation Methods 0.000 claims 40
- 239000003112 inhibitor Substances 0.000 claims 38
- 230000037361 pathway Effects 0.000 claims 24
- 108010001831 LDL receptors Proteins 0.000 claims 23
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 23
- 238000007634 remodeling Methods 0.000 claims 22
- 102000051172 Axin Human genes 0.000 claims 19
- 108700012045 Axin Proteins 0.000 claims 19
- 102100030091 Dickkopf-related protein 2 Human genes 0.000 claims 19
- 101710099523 Dickkopf-related protein 2 Proteins 0.000 claims 19
- 102100037985 Dickkopf-related protein 3 Human genes 0.000 claims 19
- 101710099550 Dickkopf-related protein 3 Proteins 0.000 claims 19
- 102100037986 Dickkopf-related protein 4 Human genes 0.000 claims 19
- 101710099554 Dickkopf-related protein 4 Proteins 0.000 claims 19
- 101100210337 Drosophila melanogaster wntD gene Proteins 0.000 claims 19
- 108091007911 GSKs Proteins 0.000 claims 19
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 19
- 102000000479 TCF Transcription Factors Human genes 0.000 claims 19
- 108010016283 TCF Transcription Factors Proteins 0.000 claims 19
- 101150109862 WNT-5A gene Proteins 0.000 claims 19
- 101150019524 WNT2 gene Proteins 0.000 claims 19
- 102000052547 Wnt-1 Human genes 0.000 claims 19
- 108700020987 Wnt-1 Proteins 0.000 claims 19
- 102000052556 Wnt-2 Human genes 0.000 claims 19
- 108700020986 Wnt-2 Proteins 0.000 claims 19
- 102000043366 Wnt-5a Human genes 0.000 claims 19
- 108700020483 Wnt-5a Proteins 0.000 claims 19
- -1 polar lipids Chemical class 0.000 claims 19
- 230000035755 proliferation Effects 0.000 claims 18
- 239000000556 agonist Substances 0.000 claims 16
- 238000007918 intramuscular administration Methods 0.000 claims 16
- 238000007912 intraperitoneal administration Methods 0.000 claims 16
- 238000001990 intravenous administration Methods 0.000 claims 16
- 238000007911 parenteral administration Methods 0.000 claims 16
- 239000004031 partial agonist Substances 0.000 claims 16
- 238000012216 screening Methods 0.000 claims 16
- 238000007920 subcutaneous administration Methods 0.000 claims 16
- 238000011200 topical administration Methods 0.000 claims 16
- 240000007113 Rumex obtusifolius Species 0.000 claims 15
- 230000002159 abnormal effect Effects 0.000 claims 15
- 230000006378 damage Effects 0.000 claims 13
- 230000004156 Wnt signaling pathway Effects 0.000 claims 12
- 108091005475 signaling receptors Proteins 0.000 claims 12
- 102000035025 signaling receptors Human genes 0.000 claims 12
- 230000000638 stimulation Effects 0.000 claims 12
- 101100485097 Xenopus laevis wnt11b gene Proteins 0.000 claims 11
- 230000001105 regulatory effect Effects 0.000 claims 11
- 238000005728 strengthening Methods 0.000 claims 11
- 230000033228 biological regulation Effects 0.000 claims 10
- 238000010276 construction Methods 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 5
- 108091005703 transmembrane proteins Proteins 0.000 claims 4
- 102000035160 transmembrane proteins Human genes 0.000 claims 4
- 239000002775 capsule Substances 0.000 claims 3
- 239000008298 dragée Substances 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 239000000499 gel Substances 0.000 claims 3
- 239000007788 liquid Substances 0.000 claims 3
- 239000006187 pill Substances 0.000 claims 3
- 239000002002 slurry Substances 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- 239000006188 syrup Substances 0.000 claims 3
- 235000020357 syrup Nutrition 0.000 claims 3
- 239000003826 tablet Substances 0.000 claims 3
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000010478 bone regeneration Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 229930014626 natural product Natural products 0.000 claims 2
- 230000002188 osteogenic effect Effects 0.000 claims 2
- 208000012868 Overgrowth Diseases 0.000 claims 1
- 244000090689 Rumex alpinus Species 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 abstract 5
- 230000008485 antagonism Effects 0.000 abstract 4
- 230000003305 autocrine Effects 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 230000003076 paracrine Effects 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 210000000963 osteoblast Anatomy 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 101000864646 Homo sapiens Dickkopf-related protein 1 Proteins 0.000 abstract 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
- 102000005431 Molecular Chaperones Human genes 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 210000002449 bone cell Anatomy 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/108—Osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/849,067 US8637506B2 (en) | 2003-09-22 | 2004-05-19 | Compositions and methods for bone formation and remodeling |
| PCT/US2005/017199 WO2005115354A2 (en) | 2004-05-19 | 2005-05-18 | Compositions and methods for bone formation and remodeling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008505190A true JP2008505190A (ja) | 2008-02-21 |
| JP2008505190A5 JP2008505190A5 (enExample) | 2008-07-03 |
Family
ID=35451375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527363A Pending JP2008505190A (ja) | 2004-05-19 | 2005-05-18 | 骨の形成と再構築のための組成物および方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8637506B2 (enExample) |
| EP (3) | EP3150255A1 (enExample) |
| JP (1) | JP2008505190A (enExample) |
| CN (1) | CN101316627A (enExample) |
| CA (6) | CA2772029C (enExample) |
| IL (1) | IL179241A (enExample) |
| WO (1) | WO2005115354A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008536816A (ja) * | 2005-03-18 | 2008-09-11 | エンゾー バイオケム，インコーポレイテッド | スクレロスチンおよびＷｎｔシグナル伝達ならびに骨形成の阻止阻害 |
| JP2010537950A (ja) * | 2006-11-14 | 2010-12-09 | エンゾー セラピューティクス， インコーポレイテッド | 骨形成および骨リモデリングのための組成物および方法 |
| KR101303941B1 (ko) | 2011-03-31 | 2013-09-05 | 연세대학교 산학협력단 | 피마자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물 |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6770461B1 (en) * | 1998-10-23 | 2004-08-03 | Genome Therapeutics Corporation | High bone mass gene of 11q13.3 |
| US6780609B1 (en) * | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
| WO2002092000A2 (en) * | 2001-05-11 | 2002-11-21 | Genome Therapeutics Corporation | Hbm variants that modulate bone mass and lipid levels |
| US20040221326A1 (en) * | 2001-05-11 | 2004-11-04 | Philip Babij | Transgenic animal model of bone mass modulation |
| US20030219793A1 (en) * | 2002-10-04 | 2003-11-27 | Carulli John P. | High bone mass gene of 11q13.3 |
| US7485460B2 (en) * | 2003-05-21 | 2009-02-03 | Tulane University Health Sciences Center | Enhanced growth of adult stem cells with Dkk-1 |
| US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US20100041599A1 (en) * | 2006-11-14 | 2010-02-18 | Dakai Liu | Compositions and methods for bone formation, bone remodeling and toxin protection |
| US9046537B2 (en) | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US20120178697A9 (en) * | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
| US8343922B2 (en) * | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| US9052324B2 (en) | 2004-05-19 | 2015-06-09 | Enzo Biochem, Inc. | Compounds and assays for controlling Wnt activity |
| BRPI0810207A2 (pt) * | 2007-04-30 | 2014-10-14 | Univ Washington | Métodos e composições para o tratamento de câncer |
| WO2008144659A2 (en) * | 2007-05-18 | 2008-11-27 | Board Of Regents, The University Of Texas System | Dickkopf-1 (dkk1) as a universal tumor vaccine for immunotherapy of cancers |
| EP2567709B1 (en) | 2007-11-02 | 2017-12-27 | Novartis AG | Molecules and methods for modulating low-density-lipoprotein receptor-related protein 6 (LRP6) |
| US8715941B2 (en) | 2007-11-16 | 2014-05-06 | Arca Biopharma, Inc. | Antibodies to LRP6 |
| US8716243B2 (en) * | 2008-05-28 | 2014-05-06 | St. Jude Childen's Research Hospital | Methods of effecting Wnt signaling through Dkk structural analysis |
| EP2408466B1 (en) * | 2009-03-18 | 2015-10-21 | The Brigham and Women's Hospital, Inc. | Dikkopf2 (Dkk2) and active fragments thereof for use in the treatment of kidney or pancreas injuries |
| SA110310369B1 (ar) | 2009-05-12 | 2014-09-02 | Pfizer | أجسام مضادة تخص dkk-1 واستخداماتها |
| ES2949159T3 (es) | 2010-05-06 | 2023-09-26 | Novartis Ag | Composiciones y métodos de uso para anticuerpos terapéuticos de proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) |
| BR112012028326A2 (pt) | 2010-05-06 | 2017-03-21 | Novartis Ag | anticorpo multivalente isolado, anticorpos biparatópicos isolados, ácido nucleico, vetor, composição farmacêutica, método de obtenção dos referidos anticorpos, bem como uso do dos mesmos |
| US11167011B2 (en) | 2010-06-07 | 2021-11-09 | Enzo Biochem, Inc. | Methods for treating bone loss using sclerostin peptides |
| US9493541B2 (en) | 2010-06-07 | 2016-11-15 | Joshua Rabbani | Antibodies specific for sulfated sclerostin |
| US9617323B2 (en) | 2010-06-07 | 2017-04-11 | Joshua Rabbani | Sulfonated sclerostin, antibodies, epitopes and methods for identification and use therefor |
| US9403882B2 (en) | 2010-06-07 | 2016-08-02 | Joshua Rabbani | Sulfation of Wnt pathway proteins |
| KR20140038358A (ko) * | 2011-01-11 | 2014-03-28 | 페이트 세러퓨틱스, 인코포레이티드 | 신규의 Wnt 조성물 및 이러한 조성물의 치료학적 용도 |
| JP2015502741A (ja) | 2011-11-04 | 2015-01-29 | ノバルティス アーゲー | 低比重リポタンパク質関連タンパク質６（ｌｒｐ６）−半減期延長構築物 |
| CN103966229A (zh) * | 2014-05-09 | 2014-08-06 | 中山大学 | bbeAMP基因、其编码的蛋白质、以bbeAMP为目的基因生产的融合蛋白及其应用 |
| US11142577B2 (en) | 2014-09-12 | 2021-10-12 | The Board Of Trustees Of The Leland Stanford Junior University | WNT signaling agonist molecules |
| CN106367517A (zh) * | 2016-09-28 | 2017-02-01 | 湖北工业大学 | 一种低密度脂蛋白受体相关蛋白5基因突变检测的试剂及应用 |
| US11746150B2 (en) | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| CN118271444A (zh) | 2017-12-19 | 2024-07-02 | 瑟罗泽恩奥普瑞汀公司 | Wnt替代分子和其用途 |
| JP7418332B2 (ja) | 2017-12-19 | 2024-01-19 | スロゼン オペレーティング， インコーポレイテッド | 抗フリズルド抗体及び使用方法 |
| CN111632147A (zh) * | 2020-06-07 | 2020-09-08 | 重庆医科大学 | 骨细胞Wnt激活剂在制备骨折加速愈合、防治骨不连及不运动或失重骨丢失药物中的应用 |
| CN115309402B (zh) * | 2022-07-13 | 2023-10-24 | 国网江苏省电力有限公司信息通信分公司 | 一种可量化差异的异构执行程序集合构成方法及装置 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002092015A2 (en) * | 2001-05-17 | 2002-11-21 | Genome Therapeutics Corporation | Reagents and methods for modulating dkk-mediated interactions |
| WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS562623A (en) * | 1979-06-21 | 1981-01-12 | Matsushita Electric Industrial Co Ltd | Electrode |
| EP0639889B1 (en) * | 1993-08-19 | 1999-09-15 | Advanced Micro Devices, Inc. | Low voltage fully differential operational amplifiers |
| US7244577B2 (en) * | 1997-04-15 | 2007-07-17 | Merck & Co., Inc. | Method of screening for modulator of LRP5 activity |
| DE19747418C1 (de) * | 1997-10-27 | 1999-07-15 | Deutsches Krebsforsch | Inhibitor-Protein des wnt-Signalwegs |
| US20040009535A1 (en) * | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| AU3510200A (en) * | 1999-03-05 | 2000-09-21 | Millennium Pharmaceuticals, Inc. | Human dickkopf-related protein and nucleic acid molecules and uses therefor |
| CA2404658A1 (en) * | 2000-03-29 | 2001-10-04 | Ismail Moarefi | 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides |
| US7713526B2 (en) * | 2001-05-01 | 2010-05-11 | The Regents Of The University Of California | Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas |
| US20040038860A1 (en) * | 2002-05-17 | 2004-02-26 | Allen Kristina M. | Reagents and methods for modulating dkk-mediated interactions |
| WO2003039534A1 (en) * | 2001-11-08 | 2003-05-15 | Merck & Co., Inc. | Compositions and methods for treating osteoporosis |
| US20050084494A1 (en) * | 2003-05-21 | 2005-04-21 | Darwin Prockop | Inhibitors of Dkk-1 |
| US20120178697A9 (en) | 2003-09-22 | 2012-07-12 | Jie Zheng | Compositions and methods for the inhibition of dishevelled proteins |
| US8367822B2 (en) | 2003-09-22 | 2013-02-05 | Enzo Therapeutics, Inc. | Compositions and methods for bone formation and remodeling |
| US8637506B2 (en) * | 2003-09-22 | 2014-01-28 | Enzo Biochem, Inc. | Compositions and methods for bone formation and remodeling |
| US8461155B2 (en) | 2003-09-22 | 2013-06-11 | University Of Connecticut | Sclerostin and the inhibition of WNT signaling and bone formation |
| US9046537B2 (en) * | 2003-09-22 | 2015-06-02 | Enzo Biochem, Inc. | Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain |
| US8343922B2 (en) * | 2004-05-19 | 2013-01-01 | Enzo Biochem, Inc. | Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells |
| AU2005267722B2 (en) * | 2004-08-04 | 2009-10-08 | Amgen Inc. | Antibodies to Dkk-1 |
| WO2006089114A2 (en) * | 2005-02-17 | 2006-08-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for treating an anthrax toxin mediated condition |
-
2004
- 2004-05-19 US US10/849,067 patent/US8637506B2/en not_active Expired - Lifetime
-
2005
- 2005-05-18 CA CA2772029A patent/CA2772029C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2771951A patent/CA2771951C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2772033A patent/CA2772033C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2567023A patent/CA2567023C/en not_active Expired - Lifetime
- 2005-05-18 JP JP2007527363A patent/JP2008505190A/ja active Pending
- 2005-05-18 CA CA2771940A patent/CA2771940C/en not_active Expired - Lifetime
- 2005-05-18 CA CA2771941A patent/CA2771941C/en not_active Expired - Lifetime
- 2005-05-18 WO PCT/US2005/017199 patent/WO2005115354A2/en not_active Ceased
- 2005-05-18 CN CNA2005800243835A patent/CN101316627A/zh active Pending
- 2005-05-18 EP EP16000780.3A patent/EP3150255A1/en not_active Withdrawn
- 2005-05-18 EP EP05751764A patent/EP1758562B1/en not_active Expired - Lifetime
- 2005-05-18 EP EP11184755.4A patent/EP2409732B1/en not_active Expired - Lifetime
-
2006
- 2006-11-13 IL IL179241A patent/IL179241A/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002092015A2 (en) * | 2001-05-17 | 2002-11-21 | Genome Therapeutics Corporation | Reagents and methods for modulating dkk-mediated interactions |
| WO2003106657A2 (en) * | 2002-06-14 | 2003-12-24 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008536816A (ja) * | 2005-03-18 | 2008-09-11 | エンゾー バイオケム，インコーポレイテッド | スクレロスチンおよびＷｎｔシグナル伝達ならびに骨形成の阻止阻害 |
| JP2010537950A (ja) * | 2006-11-14 | 2010-12-09 | エンゾー セラピューティクス， インコーポレイテッド | 骨形成および骨リモデリングのための組成物および方法 |
| KR101303941B1 (ko) | 2011-03-31 | 2013-09-05 | 연세대학교 산학협력단 | 피마자 추출물을 유효성분으로 함유하는 골 질환 예방 및 치료용 조성물 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2771951C (en) | 2014-07-08 |
| IL179241A0 (en) | 2007-03-08 |
| CA2567023A1 (en) | 2005-12-08 |
| WO2005115354A3 (en) | 2007-09-13 |
| CA2567023C (en) | 2012-07-03 |
| CA2772029C (en) | 2016-05-17 |
| CA2771941A1 (en) | 2005-12-08 |
| CN101316627A (zh) | 2008-12-03 |
| CA2772033A1 (en) | 2005-12-08 |
| US8637506B2 (en) | 2014-01-28 |
| WO2005115354A2 (en) | 2005-12-08 |
| CA2772033C (en) | 2016-05-17 |
| CA2771951A1 (en) | 2005-12-08 |
| US20050196349A1 (en) | 2005-09-08 |
| US20060198791A2 (en) | 2006-09-07 |
| EP3150255A1 (en) | 2017-04-05 |
| CA2771940C (en) | 2016-01-12 |
| CA2771940A1 (en) | 2005-12-08 |
| IL179241A (en) | 2016-04-21 |
| EP1758562A2 (en) | 2007-03-07 |
| CA2771941C (en) | 2015-03-31 |
| CA2772029A1 (en) | 2005-12-08 |
| EP1758562B1 (en) | 2012-12-05 |
| EP1758562A4 (en) | 2009-07-22 |
| EP2409732A1 (en) | 2012-01-25 |
| EP2409732B1 (en) | 2016-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008505190A (ja) | 骨の形成と再構築のための組成物および方法 | |
| JP4993623B2 (ja) | スクレロスチンおよびＷｎｔシグナル伝達ならびに骨形成の阻止阻害 | |
| Matsuoka et al. | p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. | |
| Kwon et al. | Myocilin is a modulator of Wnt signaling | |
| Semënov et al. | Head inducer Dickkopf-1 is a ligand for Wnt coreceptor LRP6 | |
| Lopez-Rios et al. | The Netrin-related domain of Sfrp1 interacts with Wnt ligands and antagonizes their activity in the anterior neural plate | |
| US7541431B2 (en) | Cristin/R-spondin ligands active in the Wnt signaling pathway and methods, compositions and kits relating thereto | |
| US20090047276A1 (en) | Methods for increasing cell or tissue regeneration in a vertebrate subject | |
| Mahapatra et al. | The trans-Golgi proteins SCLIP and SCG10 interact with chromogranin A to regulate neuroendocrine secretion | |
| US12161728B2 (en) | Reducing abnormal accumulation of TDP-43 in motor neurons in amyotrophic lateral sclerosis and/or frontotemporal dementia using a construct encoding cyclin F | |
| JP2005518222A (ja) | Ｃｄｋインヒビターによって調節される遺伝子の発現を同定および調整するための薬剤および方法 | |
| Orioli et al. | Rac3-induced neuritogenesis requires binding to Neurabin I | |
| Narita et al. | A Wnt3a variant participates in chick apical ectodermal ridge formation: distinct biological activities of Wnt3a splice variants in chick limb development | |
| Huh et al. | Muscle function and dysfunction in health and disease | |
| HK1150962A (en) | Sclerostin and the inhibition of wnt signaling and bone formation | |
| Ai | The Consequences of LRP5 Mutations on the Skeleton | |
| Masckauchan | Activation of Alternative Wnt Signaling Pathways in Human Mammary Gland and Breast Cancer Cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080514 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080514 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110418 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110712 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110720 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110812 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110819 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110907 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110914 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120116 |